Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Coronary Artery Disease IV: Preventive Measures

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Atherosclerosis I: Introduction

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cystatin C is a biomarker for predicting acute kidney injury in patients with acute-on-chronic liver failure.

World journal of gastroenterology·2014

Same author

Expression of tissue factor pathway inhibitor-2 in gastric stromal tumor and its clinical significance.

Experimental and therapeutic medicine·2014

Same author

Facile access to cytocompatible multicompartment micelles with adjustable Janus-cores from A-block-B-graft-C terpolymers prepared by combination of ROP and ATRP.

Colloids and surfaces. B, Biointerfaces·2014

Same author

Functional layers for Zn(II) ion detection: from molecular design to optical fiber sensors.

The journal of physical chemistry. B·2013

Same author

Expression of the 78 kD glucose-regulated protein is induced by endoplasmic reticulum stress in the development of hepatopulmonary syndrome.

Gene·2013

Same author

Multi-nuclear silver(I) and copper(I) complexes: a novel bonding mode for bispyridylpyrrolides.

Dalton transactions (Cambridge, England : 2003)·2013

Search research articles

Related Experiment Video

Updated: May 27, 2026

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

Probucol alleviates atherosclerosis and improves high density lipoprotein function.

Jian-Kai Zhong¹, Zhi-Gang Guo, Chen Li

¹Division of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong, PR China.

Lipids in Health and Disease

|November 15, 2011

Summary

This summary is machine-generated.

Probucol treatment improved high-density lipoprotein (HDL) function, reducing atherosclerosis progression. This hypolipidemic agent enhanced cholesterol efflux and anti-inflammatory effects, offering a potential therapeutic strategy.

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Related Experiment Videos

Last Updated: May 27, 2026

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

Cardiovascular Research
Pharmacology
Biochemistry

Background:

Probucol is a hypolipidemic drug known to decrease high-density lipoprotein cholesterol (HDL-C).
The precise mechanism by which probucol affects atherosclerosis, particularly through HDL function, remains incompletely understood.

Purpose of the Study:

To investigate the effects of probucol on high-density lipoprotein (HDL) function in the context of atherosclerosis.
To elucidate the underlying mechanisms by which probucol may hinder atherosclerosis progression.

Main Methods:

New Zealand White rabbits were assigned to control, atherosclerosis (high-fat diet), or probucol (high-fat diet + probucol) groups for 12 weeks.
Assessed cholesterol efflux, ABCA1 and SR-B1 expression in hepatocytes and macrophages, serum paraoxonase 1 and myeloperoxidase activity, and aortic morphology.
Analyzed lipid profiles and performed immunohistochemical analysis of aortas.

Main Results:

Probucol significantly increased paraoxonase 1 activity, cholesterol efflux rates, and ABCA1/SR-B1 expression in liver and immune cells compared to the atherosclerosis group.
HDL cholesterol levels, myeloperoxidase activity, and aortic intima-media thickness were reduced by probucol.
Aortic plaque area and atherosclerotic lesion severity were decreased in the probucol-treated group.

Conclusions:

Probucol alleviates atherosclerosis by enhancing high-density lipoprotein (HDL) function.
Key mechanisms involve promoting reverse cholesterol transport and improving anti-inflammatory and antioxidant properties.
These findings highlight probucol's therapeutic potential in managing atherosclerosis via HDL modulation.